# A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

> **NCT06101095** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 69 (actual)

## Conditions studied

- Eosinophilic Oesophagitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06101095
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2025-11-05
- **Final completion:** 2028-02-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101095, "A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06101095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*